Mai Kayayyakin Magunguna da Abinci Mai Gina Jiki Daga China
Kamfanin Jiangxi Serum Pharma Industries Co., Ltd. ƙwararren mai samar da magunguna da kayayyakin abinci mai gina jiki ne a ƙasar Sin. Kusan shekaru 10 kenan, mun sadaukar da kanmu wajen fitar da kayayyakin halittu, alluran rigakafi, magungunan ƙasashen yamma, kayan masarufi, magunguna masu alaƙa, abubuwan da ake amfani da su a fannin likitanci, ƙarin abinci, da kuma abubuwan da ake cirewa daga tsire-tsire, kuma mun sami ƙwarewa mai yawa a fannin.
An kafa a shekarar 2017
Sama da abokan ciniki 500 na dogon lokaci na haɗin gwiwa
Sama da masu samar da kayayyaki 200 masu alaƙa da juna
Tallace-tallace na shekara-shekara sun wuce dala miliyan 10 na Amurka
Sinadaran Abinci Mai Gina JikiYana samowa daga yanayi don kiyayewa
Lafiyar Jiki Da Daidaito Tare Da Tsarkaka
Ci gaba
Kamfanin Serum Pharma zai ci gaba da sa ido kan ci gaban kasuwannin zamani. A halin yanzu, mun riga mun yi aiki tare da abokan hulɗarmu kan keɓance sabis na Pre-Mix, Co-Crystallization da Bio-Fermentation, kuma mun ƙaddamar da ayyukan tallafi masu dacewa. Cikakkun bayanai kamar haka:
Dalilin da yasa Maganin Tabar Tetanus yake da matuƙar muhimmanci ga Dabbobi a Afirka
Gabatarwa: Barazana a Shiru ga Tattalin Arzikin Dabbobin Afirka
Afirka gida ce ga kashi ɗaya bisa uku na dabbobin duniya-Sashen kiwon dabbobi na nahiyar yana tallafawa kimantawa Mutane miliyan 350 kuma yana ba da gudummawa Kashi 12% na GDP na Afirka kuma Kashi 42% na GDP na noma.A ƙasashe kamar Kenya, dabbobi suna wakiltar kashi 42% na GDP na noma-a wasu ƙasashe, yana ba da gudummawa har zuwa kashi 80% na GDP na ƙasa-An kiyasta darajar Kasuwar Dabbobin Afirka ta kai kimanin dala biliyan 75 a shekarar 2022 kuma ana hasashen zai kai dala biliyan 125 a cikin shekaru masu zuwa..
Duk da haka a bayan waɗannan adadi masu ban mamaki akwai barazana mai ɗorewa da za a iya hanawa: tetanusYayin da cutar tetanus ta zama ruwan dare a ƙasashen da suka ci gaba saboda allurar riga-kafi ta yau da kullun-13, har yanzu yana ci gaba da zama barazana ga miliyoyin dabbobi da dabbobin aiki a faɗin AfirkaGa masu samar da kayayyakin nazarin halittu na dabbobi kamar kamfaninku — waɗanda suka riga suka sami rajistar UAE da kuma samfurin Tetanus Antitoxin (TAT) mai gasa a farashi — wannan ba wai kawai wata dama ce ta jin kai ba, har ma da babbar hanyar buɗe kasuwa.
Binciken Kasuwar Squalene da aka samo daga tsirrai
TAKARDAR FARAR: Kasuwar Squalene ta Duniya
Samar da kayayyaki masu dorewa, Tsarin Mulki, da Damar Dabaru (2025-2034)
Ranar Bugawa:Afrilu 2026
Masu Sauraron da Aka Yi Niyya:Masu Alamar Kayan Kwalliya, Sayen Magunguna, Masu Rarraba Kayan Danye
Takaitaccen Bayani na Babban Jami'i
Kasuwar squalene ta duniya tana fuskantar sauyi mai mahimmanci. Sakamakon matsin lamba a Turai, alƙawarin ESG (Muhalli, zamantakewa, da Mulki) daga manyan kamfanoni, da kuma sabbin fasahohin halittu, masana'antar tana sauyawa cikin sauri daga tushen dabbobi na gargajiya zuwa gamadadin tsirrai da halittu masu rai.https://www.jxserum.com/other-extracts/
Wannan takardar farar takarda ta bayar da nazarin bayanai kan yanayin kasuwa, tsarin dokoki (musamman haramcin da Tarayyar Turai ta yi kan squalene da aka samo daga shark a cikin kayan kwalliya), ƙalubalen sarkar samar da kayayyaki, da kuma hasashen yanayin ci gaban da za a samu nan da shekarar 2034.
Muhimman Abubuwan da aka gano:
-
Ci gaban Kasuwa:Ana hasashen cewa kasuwa za ta girma dagaDala miliyan 185.03 (2025) zuwa Dala miliyan 437.36 nan da shekarar 2034, a CAGR na 10.10% .
-
Mamayar Yanki: Turai tana da kashi 48% na kaso na kasuwar duniya, wanda dokokin dorewa masu tsauri suka haifar.
-
Rarrabawa: Kayan kwalliya suna wakiltar kashi 70.51% na amfani da su a ƙarshe, amma Magunguna (maganin rigakafi) sune ɓangaren da ke bunƙasa cikin sauri..
-
Canjin Samuwa: Squalene da aka samo daga tsirrai shine nau'in tushen da ya fi saurin girma, yana mai mayar da martani ga haramcin nau'ikan da aka samo daga dabbobi a manyan yankuna.
Dalilin da yasa Dexamethasone Sodium Phosphate API ya ci gaba da zama Muhimmin Kwayar Halitta a Magungunan Zamani






